Research Analysts Offer Predictions for Castle Biosciences, Inc.’s FY2026 Earnings (NASDAQ:CSTL)

Castle Biosciences, Inc. (NASDAQ:CSTL) – Investment analysts at Leerink Partnrs issued their FY2026 earnings per share (EPS) estimates for Castle Biosciences in a report released on Monday, August 5th. Leerink Partnrs analyst P. Souda anticipates that the company will post earnings per share of ($1.13) for the year. The consensus estimate for Castle Biosciences’ current full-year earnings is ($1.66) per share.

CSTL has been the topic of several other reports. Robert W. Baird increased their target price on shares of Castle Biosciences from $34.00 to $37.00 and gave the stock an “outperform” rating in a research note on Tuesday. Stephens reiterated an “overweight” rating and issued a $37.00 price objective on shares of Castle Biosciences in a research report on Tuesday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $32.80.

Castle Biosciences Price Performance

CSTL stock opened at $27.84 on Wednesday. The firm has a 50 day moving average of $21.54 and a 200-day moving average of $21.98. The firm has a market capitalization of $768.58 million, a P/E ratio of -24.21 and a beta of 0.93. Castle Biosciences has a 12 month low of $12.07 and a 12 month high of $28.22. The company has a current ratio of 9.25, a quick ratio of 9.02 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.47. The business had revenue of $87.00 million for the quarter, compared to analysts’ expectations of $69.95 million. Castle Biosciences had a negative return on equity of 7.91% and a negative net margin of 12.28%. During the same quarter in the prior year, the firm posted ($0.70) EPS.

Insider Activity

In related news, COO Kristen M. Oelschlager sold 12,989 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $23.06, for a total value of $299,526.34. Following the completion of the transaction, the chief operating officer now directly owns 132,836 shares in the company, valued at $3,063,198.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Castle Biosciences news, insider Derek J. Maetzold sold 2,368 shares of Castle Biosciences stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $23.40, for a total transaction of $55,411.20. Following the transaction, the insider now directly owns 57,893 shares of the company’s stock, valued at $1,354,696.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Kristen M. Oelschlager sold 12,989 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $23.06, for a total transaction of $299,526.34. Following the completion of the sale, the chief operating officer now directly owns 132,836 shares of the company’s stock, valued at approximately $3,063,198.16. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,150 shares of company stock worth $416,551. 7.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Castle Biosciences

Several hedge funds have recently added to or reduced their stakes in CSTL. Olympiad Research LP purchased a new position in shares of Castle Biosciences in the fourth quarter worth about $263,000. Principal Financial Group Inc. lifted its position in Castle Biosciences by 7.0% in the fourth quarter. Principal Financial Group Inc. now owns 1,585,673 shares of the company’s stock valued at $34,219,000 after purchasing an additional 103,503 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Castle Biosciences by 130.7% during the first quarter. Acadian Asset Management LLC now owns 210,824 shares of the company’s stock valued at $4,669,000 after purchasing an additional 119,443 shares during the period. Bellevue Group AG grew its holdings in shares of Castle Biosciences by 0.4% in the fourth quarter. Bellevue Group AG now owns 1,232,378 shares of the company’s stock worth $26,595,000 after purchasing an additional 4,347 shares during the last quarter. Finally, Harbor Capital Advisors Inc. increased its stake in shares of Castle Biosciences by 249.3% in the second quarter. Harbor Capital Advisors Inc. now owns 138,707 shares of the company’s stock worth $3,020,000 after buying an additional 99,001 shares during the period. 92.60% of the stock is owned by institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.